The Lancet
Open in Telegram
All the latest articles published on Lancet Journal Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
Show more📈 Analytical overview of Telegram channel The Lancet
Channel The Lancet (@the_lancet) in the English language segment is an active participant. Currently, the community unites 17 744 subscribers, ranking 1 322 in the Medicine category and 2 159 in the USA region.
📊 Audience metrics and dynamics
Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 17 744 subscribers.
According to the latest data from 07 September, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 206 over the last 30 days and by 0 over the last 24 hours, overall reach remains high.
- Verification status: Not verified
- Engagement rate (ER): The average audience engagement rate is 4.17%. Within the first 24 hours after publication, content typically collects 2.03% reactions from the total number of subscribers.
- Post reach: On average, each post receives 740 views. Within the first day, a publication typically gains 361 views.
- Reactions and interaction: The audience actively supports content: the average number of reactions per post is 1.
- Thematic interests: Content is focused on key topics such as cancer, patient, treatment, disease, vaccine.
📝 Description and content policy
The author describes the resource as a platform for expressing subjective opinions:
“All the latest articles published on Lancet Journal
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
Thanks to the high frequency of updates (latest data received on 08 September, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.
17 744
Subscribers
No data24 hours
+267 days
+20630 days
Data loading in progress...
Similar Channels
Tags Cloud
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
September '26
September '26
+37
in 0 channels
August '26
+239
in 0 channels
Get PRO
July '26
+336
in 1 channels
Get PRO
June '26
+337
in 0 channels
Get PRO
May '26
+416
in 0 channels
Get PRO
April '26
+287
in 0 channels
Get PRO
March '26
+149
in 0 channels
Get PRO
February '26
+156
in 0 channels
Get PRO
January '26
+199
in 2 channels
Get PRO
December '25
+206
in 0 channels
Get PRO
November '25
+283
in 4 channels
Get PRO
October '25
+78
in 1 channels
Get PRO
September '25
+20
in 0 channels
Get PRO
August '25
+35
in 0 channels
Get PRO
July '25
+26
in 1 channels
Get PRO
June '25
+30
in 0 channels
Get PRO
May '25
+9
in 0 channels
Get PRO
April '25
+29
in 0 channels
Get PRO
March '25
+31
in 4 channels
Get PRO
February '25
+20
in 0 channels
Get PRO
January '25
+21
in 6 channels
Get PRO
December '24
+168
in 0 channels
Get PRO
November '24
+559
in 8 channels
Get PRO
October '24
+567
in 9 channels
Get PRO
September '24
+805
in 3 channels
Get PRO
August '24
+777
in 5 channels
Get PRO
July '24
+1 657
in 7 channels
Get PRO
June '24
+862
in 6 channels
Get PRO
May '24
+926
in 3 channels
Get PRO
April '24
+838
in 1 channels
Get PRO
March '24
+919
in 2 channels
Get PRO
February '24
+856
in 1 channels
Get PRO
January '24
+900
in 1 channels
Get PRO
December '23
+834
in 1 channels
Get PRO
November '23
+110
in 1 channels
Get PRO
October '23
+130
in 2 channels
Get PRO
September '23
+116
in 0 channels
Get PRO
August '23
+127
in 0 channels
Get PRO
July '23
+126
in 0 channels
Get PRO
June '23
+116
in 0 channels
Get PRO
May '23
+176
in 0 channels
Get PRO
April '23
+134
in 0 channels
Get PRO
March '23
+149
in 0 channels
Get PRO
February '23
+99
in 0 channels
Get PRO
January '23
+124
in 0 channels
Get PRO
December '22
+105
in 0 channels
Get PRO
November '22
+208
in 0 channels
Get PRO
October '22
+116
in 0 channels
Get PRO
September '22
+240
in 0 channels
Get PRO
August '22
+156
in 0 channels
Get PRO
July '22
+138
in 0 channels
Get PRO
June '22
+230
in 0 channels
Get PRO
May '22
+159
in 0 channels
Get PRO
April '22
+136
in 0 channels
Get PRO
March '22
+167
in 0 channels
Get PRO
February '22
+108
in 0 channels
Get PRO
January '22
+221
in 0 channels
Get PRO
December '21
+266
in 0 channels
Get PRO
November '21
+264
in 0 channels
Get PRO
October '21
+197
in 0 channels
Get PRO
September '21
+211
in 0 channels
Get PRO
August '21
+148
in 0 channels
Get PRO
July '21
+233
in 0 channels
Get PRO
June '21
+319
in 0 channels
Get PRO
May '21
+382
in 0 channels
Get PRO
April '21
+411
in 0 channels
Get PRO
March '21
+712
in 0 channels
Get PRO
February '21
+192
in 0 channels
Get PRO
January '21
+152
in 0 channels
Get PRO
December '20
+2 519
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 07 September | +2 | |||
| 06 September | +6 | |||
| 05 September | +9 | |||
| 04 September | +4 | |||
| 03 September | +3 | |||
| 02 September | +1 | |||
| 01 September | +12 |
Channel Posts
[Articles] Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01655-7/fulltext?rss=yes
In the first fully reported phase 3 cooperative group trial to assess immunotherapy in inoperable early-stage NSCLC, we observed no improvement in overall survival with atezolizumab plus SBRT, and more grade 3 or higher adverse events were reported with atezolizumab combined with SBRT.
| 2 | [Series] The changing therapeutic landscape of small-cell lung cancer
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01244-4/fulltext?rss=yes
Small-cell lung cancer (SCLC) is an exceptionally aggressive malignancy: highly proliferative, heterogeneous, and frequently metastatic at diagnosis. Although initially responsive to chemotherapy, such responses are typically transient, and recurrent disease has been largely refractory to standard cytotoxics. The past decade has been notable for major advances in our understanding of SCLC biology, and this preclinical progress is now informing multiple novel therapeutic approaches for this disease. | 370 |
| 3 | [Review] Patient-centred and fit-for-purpose clinical trials in rare cancers: lessons from sarcomas for operationalising 2024 WHO Guidance and ICH E6(R3)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00445-1/fulltext?rss=yes
Rare cancers account for approximately one quarter of cancer diagnoses in Europe, yet prevailing clinical trial governance frameworks were developed for common malignancies and conventional randomised designs. The 2024 WHO Guidance for best practices for clinical trials and ICH E6(R3) reframe trial quality around scientific validity, ethical proportionality, feasibility, equity, and meaningful patient engagement — principles that are structurally tested by rare cancer research. This narrative review examines how these principles are operationalised in representative sarcoma trials, where biological heterogeneity, low incidence, and international collaboration expose the limits of standard approaches. | 533 |
| 4 | [Articles] Steroid, thiamine, and ascorbic acid for comatose out-of-hospital cardiac arrest survivors (STAR): a randomised, placebo-controlled, phase 2 trial
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00444-X/fulltext?rss=yes
Early administration of hydrocortisone, ascorbic acid, and thiamine did not reduce neuronal injury or improve 6-month clinical outcomes. The findings do not support empiric neuroprotective use in comatose OHCA survivors. | 549 |
| 5 | [Comment] High-quality mentorship can improve physician-scientist recruitment, retention, and career satisfaction
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01707-1/fulltext?rss=yes
Physician-scientists, who engage in both patient care and scientific inquiry, represent an increasingly small portion of the physician workforce. In the USA, only 1·3% of physicians reported research as their major professional activity in 2020.1 In the UK, clinical academics represented just 3·2% of the consultant workforce in 2025.2 | 526 |
| 6 | [Correspondence] Gold standard vaccine policy as a global health signal
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01698-3/fulltext?rss=yes
The US Executive Order of Aug 10, 2026, establishing “Gold Standard Childhood Vaccine Recommendations”,1 should be considered not only a domestic policy change but also a potential global health signal. By redefining what childhood vaccines should be routinely recommended, encouraging separation of the combined measles, mumps, and rubella vaccine, and advocating separate medical visits for different childhood immunisations, the policy risks conflating parental choice with the optimisation of evidence-based vaccination delivery. | 501 |
| 7 | [Correspondence] Integrating responders’ mental health into the Ebola outbreak response
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01738-1/fulltext?rss=yes
Ebola outbreaks place extraordinary demands on the people tasked with containing them. The ongoing Bundibugyo virus disease outbreak in the Democratic Republic of the Congo, following cross-border transmission to Uganda, is occurring amid armed conflict, population displacement, humanitarian pressures, sustained transmission, and infections and deaths among health-care workers, underscoring that outbreak control depends on a diverse workforce operating under exceptional pressure.1 Responders face infection risk, repeated exposure to severe illness and death, fear of transmitting infection to their families, long working hours, exhaustion, isolation, stigma, and sometimes hostility. | 461 |
| 8 | [Articles] Efficacy and safety of tiotropium in partial and uncontrolled preschool asthma (TIPP): a phase III, multicentre, randomised, double-blind, placebo-controlled trial
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00425-6/fulltext?rss=yes
Tiotropium did not reduce the risk of a severe asthma exacerbation, but was well tolerated as add-on therapy to ICS in preschool children with high-risk asthma. | 464 |
| 9 | [Articles] Natural language processing-based model to predict radiation pneumonitis in patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy: a retrospective cohort study
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00390-1/fulltext?rss=yes
In this early work, NLP-based extraction of longitudinal symptoms from routine clinical documentation meaningfully enhances RP prediction in patients undergoing CRT for NSCLC. This approach leverages existing electronic health record infrastructure to deliver real-time, scalable, and interpretable risk estimates, offering a pathway toward potential early intervention and personalized toxicity management. The model and DCA requires external and prospective validation before clinical deployment; as such, future work should focus on this validation and integration into clinical decision support systems. | 456 |
| 10 | [Comment] Late-onset seizures as a sentinel of Alzheimer's disease progression in Down syndrome
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00959-1/fulltext?rss=yes
Epilepsy is a common co-occurring condition in older adults with Down syndrome and frequently associated with the emergence of Alzheimer's disease-related cognitive decline.1 Likely to be under-recognised and often untreated in the earlier stages, late-onset myoclonic epilepsy in Down syndrome (LOMEDS) presents as myoclonic or tonic–clonic seizures and can be both a manifestation of underlying Alzheimer's disease pathology and an accelerator of disease progression.2 How seizure onset timing in adults with Down syndrome relates to Alzheimer's disease symptoms and progression remains unclear, complicating interpretation of decline and clinical management. | 494 |
| 11 | [Comment] Closing the preparedness gap: moving beyond emergency response to sustain the medical countermeasure ecosystem
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01768-X/fulltext?rss=yes
Infectious disease outbreaks expose weaknesses that are overlooked between crises. The ongoing Ebola virus disease outbreak caused by Bundibugyo virus (Orthoebolavirus bundibugyoense; BDBV) in the Democratic Republic of the Congo, during which there has been cross-border transmission into Uganda, has brought together governments, regional and multilateral organisations, manufacturers, research institutions, and financing partners. These actors are accelerating the development, evaluation, and deployment of medical countermeasures (MCMs), including diagnostics, vaccines, therapeutics, and personal protective equipment (PPE). | 427 |
| 12 | [Comment] Kidney xenotransplantation—bridge to allotransplantation or destination treatment?
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01479-0/fulltext?rss=yes
The shortage of human kidneys remains a central problem in transplantation, and many candidates die or are removed from the waiting list before an organ becomes available.1 Genetically engineered porcine kidneys have long been proposed to expand the donor pool,2 and over the past 3 years the field has rapidly moved from preclinical models to decedent models to living recipients.3–5 In their Article, Leonardo Riella and colleagues report a porcine kidney xenograft that supported a living human recipient for 271 days—the longest dialysis-free xenograft function described to date—followed by explantation and a subsequent deceased-donor human kidney transplantation. | 331 |
| 13 | [Articles] Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00980-3/fulltext?rss=yes
Epilepsy increases sharply after symptomatic Alzheimer's disease onset in people with Down syndrome. The association of epilepsy with reduced survival and accelerated cognitive decline underscores the need for targeted preventive and therapeutic strategies against Alzheimer's disease-related epileptogenesis and hyperexcitability. | 329 |
| 14 | [Articles] Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01295-X/fulltext?rss=yes
This case shows that porcine kidney xenotransplantation can provide prolonged renal support and be discontinued without clinically significant allosensitisation or zoonotic infection. Early cellular rejection resolved with treatment, whereas later graft failure was associated with microvascular injury progressing to thrombotic microangiopathy despite a negative donor-specific crossmatch, supporting the possibility that mechanisms beyond conventional antibody-mediated rejection contributed to late graft injury. | 377 |
| 15 | [Articles] Bundibugyo virus disease evidence map: a rapid research needs appraisal
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00432-3/fulltext?rss=yes
Whilst acknowledging the limitations of such a rapid appraisal, our findings show that urgent, coordinated investment is needed in countermeasure trials inclusive of pregnant women and children, supported by observational studies community engagement and co-production. | 375 |
| 16 | [Articles] Long-acting HIV pre-exposure prophylaxis adherence and discontinuation: a global systematic review and meta-analysis
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00442-6/fulltext?rss=yes
Adherence to LAI-PrEP remained high through 12 months, with the best adherence being observed in clinical trials, which serve as upper-bound benchmarks. Compared to LAI-PrEP, IVR-PrEP had lower adherence and higher discontinuation. Efforts facilitating longer-term adherence warrant research. | 399 |
| 17 | [Review] Artificial intelligence and machine learning in heart and lung transplantation
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00433-5/fulltext?rss=yes
Artificial intelligence (AI) and machine learning (ML) are increasingly applied across the heart and lung transplant continuum, from donor organ evaluation and waitlist prioritisation through peri-operative decision support to post-transplant rejection surveillance and personalised immunosuppression. Deep learning for endomyocardial biopsy interpretation has achieved an area under the curve (AUC) of 0.962, with performance comparable to expert pathologists, while ML-augmented ex-vivo lung perfusion platforms have demonstrated the potential to expand organ utilisation in real-world implementation studies. | 482 |
| 18 | [Articles] Effects of hearing intervention on blood-based biomarkers of neuroinflammation and neurodegeneration: a secondary analysis of the ACHIEVE randomised controlled trial
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00417-7/fulltext?rss=yes
Randomisation to hearing intervention was associated with a slower three-year rise in a blood-based biomarker of neuroinflammation. Comparable estimates were observed for neurodegeneration, although the effect was not statistically significant. Findings suggest that hearing intervention may reduce the rate of change in non-specific blood-based biomarkers associated with brain health and dementia progression. | 465 |
| 19 | [Articles] Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00443-8/fulltext?rss=yes
Long and short preoperative chemotherapy obtains similar EFS in R/BR PDAC. Future research should focus on more effective treatment regimens and explore the optimal post-operative therapy. | 548 |
| 20 | [Articles] Use of procalcitonin point-of-care testing to guide de-escalation of antibiotic therapy in adults with suspected bacterial sepsis in a tertiary hospital in Bangladesh: a randomised controlled open-label trial
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00424-4/fulltext?rss=yes
In this single-centre trial in Bangladesh, procalcitonin-guided de-escalation reduced the duration of antibiotic therapy in adults with suspected bacterial sepsis. Mortality and recurrent infection were similar between the groups, although the trial was not powered to assess these outcomes formally. This promising approach of point-of-care procalcitonin-guided antibiotic discontinuation should be evaluated further in comparable resource-limited settings. | 610 |
